• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

University College of London Hospitals - Articles and news items

UK Phase 2/3 acid sphingomyelinase deficiency trial begins

Industry news / 3 November 2016 / Niamh Louise Marriott, Digital Content Producer

Olipudase alfa is an enzyme replacement therapy being studied as a treatment of non-neurological manifestations of acid sphingomyelinase deficiency (ASMD)…


Webinar: NIR Spectroscopy for Assessing Blend Uniformity in the Pharmaceutical IndustryLEARN MORE
+ +